Home > Back to Publisher > Report Information

U.S. Anti-obesity Prescription Markets

Frost & Sullivan
September 26, 2006
115 Pages - SKU: MC1374680

Abstract Table of Contents Related Reports

Countries covered: United States

Research Overview

The Frost & Sullivan research service entitled U.S. Anti-Obesity Prescription Markets provides analysis of treated patients, market revenues, and pipeline products for the obese market. In this research service, Frost & Sullivan's expert analysts thoroughly examine emerging appetite suppressants, digestion modifiers, energy expenditure modifiers, and combination therapy approaches.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

By Application:

Appetite suppressants
Digestion modifiers
Energy expenditure modifiers
Combination therapy approaches

Market Oveview

Rapidly Growing Obese Population Increases Market Potential

With a prevalent population of 68.3 million adults in 2005, obesity has come to represent a serious healthcare epidemic in the United States. The recognition that around 80 percent of type II diabetes cases can be treated through weight loss has clearly positioned obesity as a major cause of disease, thus elevating the need to produce effective therapeutic approaches to treat this condition. This is likely to propel a treatment practice shift to long-term obesity management, whereby physicians are expected to increasingly prescribe medication as a preventative measure. Further, considering that the growth in obese patient base in being fuelled by an increase in the prevalence of patients classified as overweight, Food and Drug Administration (FDA) guidance may permit the evaluation and labeling of potential weight loss agents in the overweight population with body mass index (BMI) between 25 kg/m2 and 27 kg/m2 as per the recommendations of the American Medical Association, North American association for the study of obesity (NAASO), and the National heart, lung, and blood institute (NHLBI).

Despite these growth factors, the changing clinical trial landscape is likely to be a key restraint for market participants. The FDA is currently evaluating recent scientific and medical information and drug development initiatives in obesity to develop an amended obesity guidance document. This new guidance is expected to profoundly impact the success of current drugs in development, and could result in more stringent criteria, such as requirements for long-term safety studies, a clinical trial comparator arm beyond placebo, and greater weight-loss efficacy for market approval. "This apart, the modest efficacy of present day pharmacotherapy is also likely to deter demand," notes the analyst of this research service. "While Fen-phen has had the greatest weight loss efficacy, key components fenfluramine and dexfenfluramine have been withdrawn from market as a result of adverse cardiac effects."

Product Improvements likely to Fuel Demand

Despite the recent failure of a few anti-obesity drugs due to their side effects and inability to satisfy patient expectations, upcoming therapies are expected to revive demand for anti-obesity medication. Less than 5 percent of the obese population received pharmacotherapy in 2005, indicating a pent up demand for such products. Presently, Sanofi-Aventis’ Accomplia (rimonabant) is receiving tremendous publicity and it is expected that once launched, patients will revisit their physicians to request for a prescription of this new anti-obesity drug. Many other companies are waiting to profit from the success of Accomplia and a rich pipeline of 27 therapeutic candidates promise to heighten demand for obesity treatment in a market with considerable theoretical demand.

"With highly anticipated product launches, growing reimbursement of anti-obesity pharmacotherapy and a virtually untapped prevalent population close to 70 million, anti-obesity drug manufacturers are expected to see a sharp

increase in market revenues in the near future," says the analyst. "Future growth in the U.S. anti-obesity prescription market is likely to depend a great deal on the availability of safe effective medication and adoption of an obesity disease management strategy by healthcare providers with prevention as a key element."

1. Executive Summary
        1. Executive Summary
                  1. Introduction

2. Introduction to U.S. Anti-obesity Prescription Markets
        1. Introduction
                  1. Market Overview
                  2. Research Scope and Methodology
        2. Basic Obesity Terminologies and Definitions
                  1. Obesity Definition
                  2. Obesity Classification
                  3. Obesity Etiology
                  4. Obesity Diagnosis
        3. Market Dynamics
                  1. Market Engineering Analysis
                  2. Market Drivers
                  a. Rapidly Growing Prevalence of Overweight and Obese Population Increases Market Potential
                  b. New Improved Products Fuel Patient Demand
                  c. Evidence of Significant Health Benefits Derived from Modest Weight Loss Coupled with Growing Obesity-related Healthcare Costs Stimulates Healthcare Provider Coverage of     Pharmacotherapy
                  d. Combination Therapy Decreases Competition and Increases Efficacy and Revenue Potential
                  3. Market Restraints
                  a. Changing Clinical Trial Landscape Impedes Market Success
                  b. Modest Efficacy of Pharmacotherapy Deters Market Demand
                  c. High Cost Constrains Patient Medication Use
                  4. Market Trends
        4. Industry Challenges and Strategic Recommendations
                  1. Industry Challenges
                  2. Strategic Recommendations
        5. Frost & Sullivan Awards
                  1. Industry Innovation and Advancement of the Year
                  2. Technology Innovation of the Year Award
                  3. Product Differentiation Innovation of the Year Award

3. Market Segmentation
        1. Disease and Treatment Overview
                  1. Obesity Prevalence Forecasts
                  2. Obesity Diagnosed and Treated Patient Forecasts
                  3. Obesity Patient Compliance
                  4. Obesity Comorbid Conditions
                  5. Unmet Needs in Obesity
        2. Product Analysis
                  1. Overview of Marketed Products
                  2. Xenical and Meridia SWOT Analyses
                  3. Key Patent Expirations
        3. Competitive and Pipeline Analysis
                  1. Competitive Landscape
                  2. Competitor Profiles
                  3. Pipeline Analysis
                  4. Anticipated Launch Dates
                  5. Alliances Acquisitions and Licensing Agreements
        4. Market Forecasts
                  1. Revenue Forecasts and Assumptions
                  2. Pricing Trends
                  3. Market Share Analysis

4. Appendix
        1. Decision Support Databases
                  1. Total Population
                  2. Prevalence of Diabetes Mellitus
                  3. Diabetes Incidence
                  4. Prevalence of Obesity
                  5. Mortality Due to Coronary Heart Disease

List of Figures

Chapter 2

Anti-obesity Prescription Market: Classification of Overweight and Obese by Body Mass Index (U.S.), 2005
Anti-obesity Prescription Markets: Market Drivers Ranked in Order of Impact (U.S.), 2006-2012
Anti-obesity Prescription Market: Market Restraints Ranked in Order of Impact (U.S.), 2006-2012
Anti-obesity Prescription Market: Impact of Top Industry Challenges (U.S.), 2006-2012
Anti-obesity Prescription Market: Industry Challenges and Strategic Recommendations (U.S.), 2006-2012

Chapter 3

Anti-obesity Prescription Market: Obesity Prevalence Forecasts (U.S.), 2002-2012
Anti-obesity Prescription Market: Obesity Statistics for States with Highest Obesity Prevalence - Available Averages (U.S.), 2002-2012
Anti-obesity Prescription Market: Treated Patients Forecasts (U.S.), 2002-2012
Anti-obesity Prescription Market: Annual Cost of Therapy versus Compliance (U.S.), 2002-2005
Anti-obesity Prescription Market: Guidelines for Obesity Treatment Selection (U.S.), 2005
Anti-obesity Prescription Market: Bariatric Surgeries by Gender (U.S.), 1998 and 2002
Anti-obesity Prescription Market: Bariatric Surgeries by Age Group (U.S.), 1998 and 2002
Anti-obesity Prescription Market: Medications on the Market (U.S.), 2005
Anti-obesity Prescription Market: Comparison of Xenical and Meridia (U.S.), 2005
Anti-obesity Prescription Market: Current Medications in Development (U.S.), 2005
Anti-obesity Prescription Market: Analysis of Alliances and Acquisitions (U.S.), 2005
Anti-obesity Prescription Market: Revenues by Product Category (U.S.), 2003-2005
Anti-Obesity Prescription Market: Revenue Forecast (U.S.), 2002-2012
Anti-obesity Prescription Market: Monthly Cost of Therapy for Select Medications (U.S.), 2005
Anti-obesity Prescription Market: Market Share Analysis (U.S.), 2005

More United States Prescription Drugs Reports

2012 Healthcare Business Market Research Handbook by Richard K. Miller & Associates
The 2012 Healthcare Business Market Research Handbook presents a comprehensive analysis of the $2.8 trillion U.S. healthcare marketplace with the most recent statistics and data ...

Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report by IBISWorld
Brand Name Pharmaceutical Manufacturing in the US Prescription for growth With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience ...

Analysis of the United States Contract Manufacturing Outsourcing Market by Frost & Sullivan
Contract manufacturing outsourcing (CMO) companies provide independent manufacturing services for pharmaceutical and biotechnological markets. This study covers the U.S. commercial manufacturing and packaging of pharmaceutical ...

United States Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Economics and politics are increasingly exerting an influence on the US pharmaceuticalmarket. This is in stark contrast to the late 1990s and early ...

The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment by AM Mindpower Solutions
EXECUTIVE SUMMARY The report titled “The US Pharmaceutical Market Outlook to 2015 – Evolving Opportunities in the Biologics Segment” provides a comprehensive analysis on the Pharmaceutical ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>

U.S. Anti-obesity Prescription Markets

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service